Literature DB >> 33629198

Dysbiotic stress increases the sensitivity of the tumor vasculature to radiotherapy and c-Met inhibitors.

Samir V Jenkins1, Mohammad Alimohammadi1, Alexia S Terry1, Robert J Griffin1, Alan J Tackett2,3, Justin W Leung1, Kieng B Vang4, Stephanie D Byrum2,3, Ruud P M Dings5,6.   

Abstract

Antibiotic-induced microbial imbalance, or dysbiosis, has systemic and long-lasting effects on the host and response to cancer therapies. However, the effects on tumor endothelial cells are largely unknown. Therefore, the goal of the current study was to generate matched B16-F10 melanoma associated endothelial cell lines isolated from mice with and without antibiotic-induced dysbiosis. After validating endothelial cell markers on a genomic and proteomic level, functional angiogenesis assays (i.e., migration and tube formation) also confirmed their vasculature origin. Subsequently, we found that tumor endothelial cells derived from dysbiotic mice (TEC-Dys) were more sensitive to ionizing radiotherapy in the range of clinically-relevant hypofractionated doses, as compared to tumor endothelial cells derived from orthobiotic mice (TEC-Ortho). In order to identify tumor vasculature-associated drug targets during dysbiosis, we used tandem mass tag mass spectroscopy and focused on the statistically significant cellular membrane proteins overexpressed in TEC-Dys. By these criteria c-Met was the most differentially expressed protein, which was validated histologically by comparing tumors with or without dysbiosis. Moreover, in vitro, c-Met inhibitors Foretinib, Crizotinib and Cabozantinib were significantly more effective against TEC-Dys than TEC-Ortho. In vivo, Foretinib inhibited tumor growth to a greater extent during dysbiosis as compared to orthobiotic conditions. Thus, we surmise that tumor response in dysbiotic patients may be greatly improved by targeting dysbiosis-induced pathways, such as c-Met, distinct from the many targets suppressed due to dysbiosis.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V. part of Springer Nature.

Entities:  

Keywords:  Dysbiosis; Endothelial cells; Foretinib; Hypofractionated radiation; Tandem mass tag mass spectroscopy; Tumor microenvironment; c-MET inhibitors

Mesh:

Substances:

Year:  2021        PMID: 33629198      PMCID: PMC8295215          DOI: 10.1007/s10456-021-09771-z

Source DB:  PubMed          Journal:  Angiogenesis        ISSN: 0969-6970            Impact factor:   10.658


  44 in total

Review 1.  Tumor endothelial cells.

Authors:  Andrew C Dudley
Journal:  Cold Spring Harb Perspect Med       Date:  2012-03       Impact factor: 6.915

2.  Gastrointestinal Tract Dysbiosis Enhances Distal Tumor Progression through Suppression of Leukocyte Trafficking.

Authors:  Kieng B Vang; Ruud P M Dings; Samir V Jenkins; Michael S Robeson; Robert J Griffin; Charles M Quick; Eric R Siegel; Martin J Cannon
Journal:  Cancer Res       Date:  2019-10-07       Impact factor: 12.701

3.  Antibiotic use predicts an increased risk of cancer.

Authors:  Annamari Kilkkinen; Harri Rissanen; Timo Klaukka; Eero Pukkala; Markku Heliövaara; Pentti Huovinen; Satu Männistö; Arpo Aromaa; Paul Knekt
Journal:  Int J Cancer       Date:  2008-11-01       Impact factor: 7.396

4.  Compartmentalized control of skin immunity by resident commensals.

Authors:  Shruti Naik; Nicolas Bouladoux; Christoph Wilhelm; Michael J Molloy; Rosalba Salcedo; Wolfgang Kastenmuller; Clayton Deming; Mariam Quinones; Lily Koo; Sean Conlan; Sean Spencer; Jason A Hall; Amiran Dzutsev; Heidi Kong; Daniel J Campbell; Giorgio Trinchieri; Julia A Segre; Yasmine Belkaid
Journal:  Science       Date:  2012-07-26       Impact factor: 47.728

5.  The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide.

Authors:  Sophie Viaud; Fabiana Saccheri; Grégoire Mignot; Takahiro Yamazaki; Romain Daillère; Dalil Hannani; David P Enot; Christina Pfirschke; Camilla Engblom; Mikael J Pittet; Andreas Schlitzer; Florent Ginhoux; Lionel Apetoh; Elisabeth Chachaty; Paul-Louis Woerther; Gérard Eberl; Marion Bérard; Chantal Ecobichon; Dominique Clermont; Chantal Bizet; Valérie Gaboriau-Routhiau; Nadine Cerf-Bensussan; Paule Opolon; Nadia Yessaad; Eric Vivier; Bernhard Ryffel; Charles O Elson; Joël Doré; Guido Kroemer; Patricia Lepage; Ivo Gomperts Boneca; François Ghiringhelli; Laurence Zitvogel
Journal:  Science       Date:  2013-11-22       Impact factor: 47.728

6.  Microbiota modulate tumoral immune surveillance in lung through a γδT17 immune cell-dependent mechanism.

Authors:  Min Cheng; Liting Qian; Guodong Shen; Geng Bian; Tingjuan Xu; Weiping Xu; Gan Shen; Shilian Hu
Journal:  Cancer Res       Date:  2014-06-19       Impact factor: 12.701

Review 7.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

8.  Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12.

Authors:  Mireia Uribe-Herranz; Kyle Bittinger; Stavros Rafail; Sonia Guedan; Stefano Pierini; Ceylan Tanes; Alex Ganetsky; Mark A Morgan; Saar Gill; Janos L Tanyi; Frederic D Bushman; Carl H June; Andrea Facciabene
Journal:  JCI Insight       Date:  2018-02-22

9.  Host dysbiosis negatively impacts IL-9-producing T-cell differentiation and antitumour immunity.

Authors:  Rafael Ribeiro Almeida; Raquel de Souza Vieira; Angela Castoldi; Fernanda Fernandes Terra; Amanda Campelo L Melo; Maria Cecília Campos Canesso; Luísa Lemos; Marcella Cipelli; Nisha Rana; Meire Ioshie Hiyane; Erika L Pearce; Flaviano Dos Santos Martins; Ana Maria Caetano de Faria; Niels Olsen Saraiva Câmara
Journal:  Br J Cancer       Date:  2020-06-05       Impact factor: 7.640

Review 10.  Microbiota dysbiosis in lung cancer: evidence of association and potential mechanisms.

Authors:  Nana Xu; Lei Wang; Chenxi Li; Chao Ding; Cong Li; Wenting Fan; Chen Cheng; Bing Gu
Journal:  Transl Lung Cancer Res       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.